Q2 2022 EPS Estimates for Integra LifeSciences Holdings Co. (NASDAQ:IART) Raised by Analyst

Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating) – Analysts at Oppenheimer boosted their Q2 2022 EPS estimates for shares of Integra LifeSciences in a research report issued on Wednesday, April 27th. Oppenheimer analyst S. Lichtman now forecasts that the life sciences company will earn $0.79 per share for the quarter, up from their prior estimate of $0.78. Oppenheimer also issued estimates for Integra LifeSciences’ Q3 2022 earnings at $0.85 EPS, Q4 2022 earnings at $0.92 EPS and FY2023 earnings at $3.68 EPS.

Integra LifeSciences (NASDAQ:IARTGet Rating) last announced its earnings results on Wednesday, April 27th. The life sciences company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.06. The business had revenue of $376.60 million during the quarter, compared to the consensus estimate of $362.19 million. Integra LifeSciences had a net margin of 10.96% and a return on equity of 16.93%. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.69 earnings per share.

Several other equities analysts have also recently commented on the company. Bank of America increased their target price on Integra LifeSciences from $55.00 to $65.00 and gave the company an “underperform” rating in a research note on Tuesday, January 18th. Truist Financial downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating and dropped their target price for the stock from $72.00 to $71.00 in a research report on Wednesday, April 13th. Piper Sandler lowered their price objective on Integra LifeSciences from $72.00 to $66.00 in a report on Wednesday, February 23rd. Finally, StockNews.com lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Friday, April 22nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $75.56.

NASDAQ:IART opened at $62.35 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.46 and a current ratio of 3.39. Integra LifeSciences has a one year low of $59.78 and a one year high of $76.70. The business’s 50-day simple moving average is $64.57 and its 200 day simple moving average is $66.20. The stock has a market cap of $5.18 billion, a price-to-earnings ratio of 31.49, a price-to-earnings-growth ratio of 2.05 and a beta of 1.14.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. CIBC Asset Management Inc boosted its position in shares of Integra LifeSciences by 4.7% in the fourth quarter. CIBC Asset Management Inc now owns 3,558 shares of the life sciences company’s stock worth $238,000 after buying an additional 160 shares during the period. Advisor Group Holdings Inc. boosted its holdings in shares of Integra LifeSciences by 2.4% during the third quarter. Advisor Group Holdings Inc. now owns 7,376 shares of the life sciences company’s stock worth $506,000 after purchasing an additional 175 shares during the period. State of Michigan Retirement System grew its position in Integra LifeSciences by 1.1% during the fourth quarter. State of Michigan Retirement System now owns 18,466 shares of the life sciences company’s stock valued at $1,237,000 after purchasing an additional 200 shares in the last quarter. NorthCrest Asset Manangement LLC increased its stake in Integra LifeSciences by 1.5% in the 1st quarter. NorthCrest Asset Manangement LLC now owns 13,800 shares of the life sciences company’s stock valued at $887,000 after buying an additional 200 shares during the period. Finally, Campbell Newman Asset Management Inc. increased its stake in Integra LifeSciences by 1.9% in the 1st quarter. Campbell Newman Asset Management Inc. now owns 12,743 shares of the life sciences company’s stock valued at $819,000 after buying an additional 243 shares during the period. Hedge funds and other institutional investors own 90.98% of the company’s stock.

In other Integra LifeSciences news, COO Glenn Coleman sold 6,268 shares of the company’s stock in a transaction on Monday, April 4th. The stock was sold at an average price of $66.04, for a total value of $413,938.72. Following the transaction, the chief operating officer now owns 41,288 shares of the company’s stock, valued at $2,726,659.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Tru St Partnership, L.P. sold 75,000 shares of the stock in a transaction on Wednesday, February 9th. The shares were sold at an average price of $65.82, for a total value of $4,936,500.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 231,268 shares of company stock worth $15,050,939. 4.20% of the stock is owned by corporate insiders.

About Integra LifeSciences (Get Rating)

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.

Recommended Stories

Earnings History and Estimates for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.